Stay updated with breaking news from Mark Mintun. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in Bernstein's Second Annual Operational Decisions Conference on Thursday, Nov. 4, 2021....
Thomson Reuters But the drug missed most of the secondary trial goals, including one watched by experts. An Eli Lilly executive told Insider the data was mixed, but very exciting. The latest test of Eli Lilly's Alzheimer's disease drug ended with a mixed bag of results that disappointed investors. Lilly gave an in-depth look at the performance of its drug, called donanemab, on Saturday at the International Conference on Alzheimer's and Parkinson's Diseases. The drug met the trial's primary goals, reducing a harmful substance that builds up in the brains of pa...
Data from Lilly at International Conference on Alzheimer's & Parkinson Diseases 2021™ (AD/PD™ 2021) to Showcase Clinical Advances in Alzheimer's Disease Research Highlights include results from the Phase 2 Trailblazer-ALZ study for donanemab News provided by Share this article Share this article INDIANAPOLIS, March 9, 2021 /PRNewswire/ -- New data from 10 studies will be presented by Eli Lilly and Company (NYSE: LLY) at the upcoming virtual International Conference on Alzheimer's & Parkinson Diseases ™ 2021 (AD/PD ™ 2021), March 9-14, 2021. Lilly will present detailed results of th...
Indianapolis-based Eli Lilly and Co. (NYSE: LLY) has entered into a licensing agreement with a Japanese pharmaceutical company to further develop and market a treatment for chronic pain. Lilly and Tok